您的购物车当前为空
Inarigivir (ORI-9020) is a dinucleotide that can significantly reduce liver HBV DNA.
别名 SB-9000, ORI-9020
Inarigivir (ORI-9020) is a dinucleotide that can significantly reduce liver HBV DNA.

| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 mg | ¥ 10,600 | 1-2周 | |
| 50 mg | ¥ 13,800 | 1-2周 | |
| 100 mg | ¥ 17,500 | 1-2周 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
凭借在化合物合成方面的丰富经验,我们可以根据您的研究需求为该产品提供快速定制合成服务。
| 产品描述 | Inarigivir (ORI-9020) is a dinucleotide that can significantly reduce liver HBV DNA. |
| 体外活性 | Inarigivir (100 mg/kg/day, I.p.) significantly reduces viral DNA in the liver and shows anti-HBV activity similar to ADV positive control. Inarigivir does not affect levels of HBV RNA in the liver, levels of HBeAg in serum, or mean titers of HBsAg. The minimal effective dose is identified to be between 1.6 and 0.5 mg/kg/day using liver HBV DNA values. |
| 动物实验 | For the first animal experiment, Inarigivir is prepared fresh daily at a dosage of 100 mg/kg of body weight /day, which is equal to 170 mol/kg/day and is injected intraperitoneally (i.p.) using cremaphor-ethanol-saline (CES) (10:10:80) or physiological saline as vehicles. ADV, the positive control, is prepared using the CES vehicle. A dosage of 10 mg/kg/day (19.9 mol/kg/day) is used. In the second experiment to determine the minimal effective concentration, Inarigivir is prepared in sterile saline in onehalf-log dilutions from 50 to 0.05 mg/kg/day. The drug is delivered i.p. in a volume of 0.1 ml. Liver samples are analyzed for HBV DNA, HBV RNA, and HBcAg, and serum samples are processed for HBV DNA, HBeAg, and HBsAg. |
| 别名 | SB-9000, ORI-9020 |
| 分子量 | 587.5 |
| 分子式 | C20H26N7O10PS |
| CAS No. | 475650-36-3 |
| Smiles | O(C)[C@H]1[C@@H](O[C@H](CO)[C@H]1OP(OC[C@H]2O[C@H](C[C@@H]2O)N3C=4C(N=C3)=C(N)N=CN4)(=O)S)N5C(=O)NC(=O)C=C5 |
| 密度 | 1.98 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year 实际储存温度请以COA为准 |
| 溶解度信息 | DMSO: Soluble |
对于不同动物的给药剂量换算,您也可以参考 更多